Hexarelin
Hexarelin is a small synthetic peptide studied for its ability to prompt the pituitary gland to release growth hormone, similar to other peptides in its class. What sets it apart in the research is a second, separate effect on heart tissue that appears to happen independently of growth hormone at all.
- Sequence
- 6 amino acids
- Format
- Lyophilized powder
- Half-Life
- Short; reported in the range of tens of minutes in animal studies
What Is Hexarelin?
Hexarelin is a synthetic hexapeptide, meaning it's built from a chain of six amino acids, belonging to a family of compounds called growth hormone-releasing peptides (GHRPs). Like others in this family, it was developed to stimulate the pituitary gland's release of growth hormone by acting on the same receptor that the body's natural hunger hormone, ghrelin, uses.
What makes hexarelin stand out in the research literature is a second binding site discovered in heart tissue, separate from the growth hormone pathway entirely. This has made it one of the more studied GHRPs specifically in cardiovascular research, alongside its growth hormone-related research.
What Hexarelin Is Being Researched For
Growth Hormone Release
Like other peptides in its class, hexarelin has been studied for its ability to trigger pituitary growth hormone release through the ghrelin receptor pathway.
Cardiac Tissue Research
A significant body of hexarelin-specific research has focused on its effects on heart tissue, including studies on coronary blood vessel activity and protection of heart muscle during periods of reduced blood flow.[1][2]
Cell Protection Research
Beyond the heart specifically, hexarelin and related GHRPs have been studied more broadly for cell-protective effects across different tissue types, an area of research that has developed over several decades.[3]
How Hexarelin Works
Triggering Growth Hormone Release
Research points to hexarelin activating the ghrelin receptor on pituitary cells, the same receptor pathway used by other growth hormone-releasing peptides, which triggers a signaling cascade leading to growth hormone secretion.
A Separate Heart Tissue Pathway
Research points to hexarelin also binding to a distinct receptor called CD36, found in heart muscle and blood vessel cells, which is unrelated to the growth hormone pathway. Studies in animal models found that hexarelin still produced protective cardiac effects even when the growth hormone pathway was blocked, suggesting the two effects work independently of each other.[1][2]
Reconstitution and Handling
Hexarelin is typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.
Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.
Key Takeaways
Hexarelin stands out among growth hormone-releasing peptides for its well-documented second pathway in cardiac tissue, working through a receptor called CD36 that's entirely separate from growth hormone signaling. Its research base spans both pituitary growth hormone release and cardioprotective effects studied specifically in animal models of heart injury. The cardiac research in particular distinguishes it from other peptides in its class that act only through the growth hormone pathway.
Frequently Asked Questions
What Is Hexarelin Derived From?
It's a synthetic peptide, a chain of six amino acids, developed as part of a family of growth hormone-releasing peptides.
What Has Hexarelin Been Studied For?
Research has focused on both pituitary growth hormone release and a separate, well-documented effect on cardiac tissue that appears independent of growth hormone.
How Does Hexarelin Work?
Research points to it activating the ghrelin receptor to trigger growth hormone release, and separately binding a receptor called CD36 in heart tissue linked to cardioprotective effects.
Why Is Hexarelin Studied Differently from Other GHRPs?
Its interaction with CD36 in cardiac tissue is more thoroughly documented than in most other peptides in its class, making it a specific subject of cardiovascular research beyond growth hormone.
Has Hexarelin Been Tested in Humans?
Most of the cardiac-specific research on hexarelin comes from animal models. Human research has focused primarily on its growth hormone-releasing properties.
Sources and Research
- Bodart V, Febbraio M, Demers A, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002;90(8):844-849.
- Locatelli V, Rossoni G, Schweiger F, Torsello A, de Gennaro Colonna V, Bernareggi M, Deghenghi R, Müller EE, Berti F. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140(9):4024-4031.
- Berlanga-Acosta J, Abreu-Cruz A, García-del Barco Herrera D, et al. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Clin Med Insights Cardiol. 2017;11:1179546817694558.
Related Reading
For educational and research purposes only. Not medical advice. Always consult a licensed healthcare professional before starting any protocol.